Equillium (0A4D) Share Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0A4D Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Equillium

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0A4D Stock 12 Month Forecast

Average Price Target

$11.60

▲(413.27% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Equillium in the last 3 months. The average price target is $11.60 with a high forecast of $20.00 and a low forecast of $7.00. The average price target represents a 413.27% change from the last price of $2.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.578,2.9950769230769234,4.4121538461538465,5.82923076923077,7.246307692307693,8.663384615384615,10.080461538461538,11.497538461538461,12.914615384615384,14.331692307692308,15.74876923076923,17.165846153846154,18.582923076923077,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.578,2.348923076923077,3.119846153846154,3.890769230769231,4.661692307692308,5.432615384615385,6.203538461538462,6.974461538461539,7.745384615384616,8.516307692307691,9.287230769230769,10.058153846153846,10.829076923076922,{"y":11.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.578,1.9950769230769232,2.412153846153846,2.829230769230769,3.2463076923076923,3.663384615384615,4.080461538461538,4.497538461538461,4.914615384615384,5.3316923076923075,5.748769230769231,6.165846153846154,6.582923076923077,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.475,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.425,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.901,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.525,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.548,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.202,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.578,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$11.60

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$20

Buy

784.96%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)

Adam Walsh

Roth MKM

$12

Buy

430.97%

Upside

Reiterated

10/06/26

Roth MKM Sticks to Its Buy Rating for Equillium (EQ)

Steven Seedhouse

Cantor Fitzgerald

$10

Buy

342.48%

Upside

Reiterated

08/14/26

Equillium (EQ) Gets a Buy from Cantor Fitzgerald

Leland Gershell

Oppenheimer

Buy

209.73%

Upside

Assigned

08/14/26

Oppenheimer Sticks to Their Buy Rating for Equillium (EQ)

Kaveri Pohlman

Clear Street

Buy

298.23%

Upside

Reiterated

08/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

William Wood

B. Riley Securities

Buy

165.49%

Upside

Reiterated

06/02/26

Equillium (EQ) Receives a Buy from B. Riley Securities

Thomas Smith

Leerink Partners

Buy

165.49%

Upside

Upgraded

05/28/26

Equillium upgraded to Outperform from Market Perform at LeerinkEquillium upgraded to Outperform from Market Perform at Leerink

Alex Thompson CFA

Stifel Nicolaus

Buy

121.24%

Upside

Reiterated

05/28/26

Analysts' Top Healthcare Picks: Aligos Therapeutics (ALGS), Equillium (EQ)

Martin Auster

Raymond James

$6→$7

Buy

209.73%

Upside

Reiterated

05/28/26

Equillium price target raised to $7 from $6 at Raymond JamesEquillium price target raised to $7 from $6 at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$20

Buy

784.96%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)

Adam Walsh

Roth MKM

$12

Buy

430.97%

Upside

Reiterated

10/06/26

Roth MKM Sticks to Its Buy Rating for Equillium (EQ)

Steven Seedhouse

Cantor Fitzgerald

$10

Buy

342.48%

Upside

Reiterated

08/14/26

Equillium (EQ) Gets a Buy from Cantor Fitzgerald

Leland Gershell

Oppenheimer

Buy

209.73%

Upside

Assigned

08/14/26

Oppenheimer Sticks to Their Buy Rating for Equillium (EQ)

Kaveri Pohlman

Clear Street

Buy

298.23%

Upside

Reiterated

08/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

William Wood

B. Riley Securities

Buy

165.49%

Upside

Reiterated

06/02/26

Equillium (EQ) Receives a Buy from B. Riley Securities

Thomas Smith

Leerink Partners

Buy

165.49%

Upside

Upgraded

05/28/26

Equillium upgraded to Outperform from Market Perform at LeerinkEquillium upgraded to Outperform from Market Perform at Leerink

Alex Thompson CFA

Stifel Nicolaus

Buy

121.24%

Upside

Reiterated

05/28/26

Analysts' Top Healthcare Picks: Aligos Therapeutics (ALGS), Equillium (EQ)

Martin Auster

Raymond James

$6→$7

Buy

209.73%

Upside

Reiterated

05/28/26

Equillium price target raised to $7 from $6 at Raymond JamesEquillium price target raised to $7 from $6 at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

IMUXImmunic

REPLReplimune Group

OVIDOvid Therapeutics

CELCCelcuity

ARDXArdelyx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Equillium

3 Months

Thomas SmithLeerink Partners

Success Rate

6/17 ratings generated profit

Average Return

+9.62%

Copying Thomas Smith's trades and holding each position for 3 Months would result in 35.29% of your transactions generating a profit, with an average return of +9.62% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

5/17 ratings generated profit

Average Return

-2.10%

Copying Thomas Smith's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -2.10% per trade.

2 Years

Thomas SmithLeerink Partners

Success Rate

1/17 ratings generated profit

Average Return

-48.36%

Copying Thomas Smith's trades and holding each position for 2 Years would result in 5.88% of your transactions generating a profit, with an average return of -48.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A4D Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0A4D has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0A4D average Analyst price target in the past 3 months is 11.60.

Each month's total comprises the sum of three months' worth of ratings.

0A4D Financial Forecast

0A4D Earnings Forecast

Next quarter’s earnings estimate for 0A4D is -$0.05 with a range of -$0.06 to -$0.04. The previous quarter’s EPS was -$0.04. 0A4D beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A4D has Performed in-line its overall industry.

0A4D Sales Forecast

Next quarter’s sales forecast for 0A4D is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. 0A4D beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A4D has Performed in-line its overall industry.

0A4D Stock Forecast FAQ

What is GB:0A4D’s average 12-month price target, according to analysts?

Based on analyst ratings, Equillium Inc’s 12-month average price target is 11.60.

What is GB:0A4D’s upside potential, based on the analysts’ average price target?

Equillium Inc has 413.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Equillium Inc a Buy, Sell or Hold?

Equillium Inc has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Equillium Inc’s share price target?

The average share price target for Equillium Inc is 11.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $20.00 ,and the lowest forecast is $7.00. The average share price target represents 413.27% Increase from the current price of $2.26.

What do analysts say about Equillium Inc?

Equillium Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Equillium Inc?

To buy shares of GB:0A4D, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Equillium (0A4D) Share Forecast & Price Target

0A4D Analyst Ratings

0A4D Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Equillium

0A4D Analyst Recommendation Trends

0A4D Financial Forecast

0A4D Earnings Forecast

0A4D Sales Forecast

0A4D Stock Forecast FAQ

Detailed List of Analyst Forecasts